EUVIMEDEUVIMED entdecken
Open Access

HML-2 env knockdown by AAV9-mediated miRNAs attenuates amyotrophic lateral sclerosis-like manifestations in mice

Myoung-Hwa Lee, Wenxue Li, Kevon Sampson, Stephanie Choi, Melina Jones, Joseph Steiner, Avindra Nath iD

Brain · 04.11.2026 · 149 (11) · 3968-3982

DOI: 10.1093/brain/awag102 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, online erschienen am 14.03.2026. Verfasst von Myoung-Hwa Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA. Hauptthemen laut MEDLINE: MicroRNAs, Amyotrophic Lateral Sclerosis, Endogenous Retroviruses. Die Arbeit nennt 84 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, NINDS NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease, for which there is no cure. Although the precise aetiology of ALS remains elusive, growing evidence suggests a pathogenic role for human endogenous retrovirus-K (HERV-K) in ALS. Expression of HERV-K subtype HML-2 envelope protein in neurons causes neurotoxicity in vitro and induces ALS-like symptoms in mice. We investigated the use of adeno-associated virus-9 (AAV9)-mediated artificial microRNA (amiRNA) targeting the HML-2 env gene in an ALS mouse model. From an in vitro screen of amiRNAs targeting the HML-2 env gene, three were chosen and inserted in tandem into an AAV9 vector and validated in vitro. This approach provided robust silencing of the transgene, with tandem amiRNA achieving robust reduction in gene and protein expression levels. Its therapeutic effectiveness was tested in an HML-2 Env transgenic mouse model, in which the env gene is expressed under the neuron-specific thy1 promoter and develops an ALS-like phenotype. A single intracerebroventricular injection of AAV9 vector encoding the amiRNAs into the mice at postnatal Day 1 effectively reduced HML-2 Env expression in the brain and spinal cord at 84 days post-injection, which was the latest time point studied. Knockdown of HML-2 env decreased the loss of cortical and spinal motor neurons and alleviated muscle fibre degeneration and fibre-type grouping. This led to improved motor function. Our results provide compelling evidence supporting the use of multiple amiRNAs delivered in an AAV9 vector for treating forms of ALS linked to HML-2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsAmyotrophic Lateral SclerosisEndogenous RetrovirusesAnimalsMiceMice, TransgenicDependovirusDisease Models, AnimalHumansGene Knockdown TechniquesGenetic VectorsMotor NeuronsGenetic TherapyGene Therapy AgentsSpinal Cord

Stichwörter der Autor:innen

RNA interferenceadenovirusendogenous retroviral elementsgene therapymotor neuron diseasetransposable elements

Substanzen

MicroRNAs

Autor:innen und Institutionen

  • National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA.

ORCID-Profile: Avindra Nath

Förderung

  • Intramural NIH HHS
  • NINDS NIH HHS
  • NIH HHS
  • National Institutes of Health
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Lee, M. H., Li, W., Sampson, K., Choi, S., Jones, M., Steiner, J., & Nath, A. (2026). HML-2 env knockdown by AAV9-mediated miRNAs attenuates amyotrophic lateral sclerosis-like manifestations in mice. Brain, 149(11), 3968-3982. https://doi.org/10.1093/brain/awag102

Vancouver

Lee MH, Li W, Sampson K, Choi S, Jones M, Steiner J, et al. HML-2 env knockdown by AAV9-mediated miRNAs attenuates amyotrophic lateral sclerosis-like manifestations in mice. Brain. 2026;149(11):3968-3982. doi:10.1093/brain/awag102

BibTeX
@article{Lee2026,
  author = {Lee, Myoung-Hwa and Li, Wenxue and Sampson, Kevon and Choi, Stephanie and Jones, Melina and Steiner, Joseph and Nath, Avindra},
  title = {HML-2 env knockdown by AAV9-mediated miRNAs attenuates amyotrophic lateral sclerosis-like manifestations in mice},
  journal = {Brain},
  year = {2026},
  volume = {149},
  number = {11},
  pages = {3968--3982},
  doi = {10.1093/brain/awag102}
}
Kostenlos starten →